GRAIL, Inc. $GRAL Stock: Profund Advisors LLC Trims Stake

Profund Advisors LLC reduced its stake in shares of GRAIL, Inc. (NASDAQ:GRAL) by 24.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,218 shares of the company’s stock after selling 4,860 shares during the period. Profund Advisors LLC’s holdings in GRAIL were worth $2,132,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of GRAL. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in shares of GRAIL by 2.3% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 17,550 shares of the company’s stock worth $2,459,000 after purchasing an additional 400 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in GRAIL by 21.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,350 shares of the company’s stock valued at $1,550,000 after buying an additional 2,020 shares during the last quarter. North Star Investment Management Corp. increased its holdings in GRAIL by 809.1% in the third quarter. North Star Investment Management Corp. now owns 300 shares of the company’s stock valued at $42,000 after buying an additional 267 shares during the last quarter. Simplify Asset Management Inc. acquired a new stake in GRAIL during the third quarter valued at approximately $6,021,000. Finally, Apollon Wealth Management LLC acquired a new stake in GRAIL during the third quarter valued at approximately $226,000.

GRAIL Price Performance

GRAL opened at $143.43 on Monday. The firm has a market cap of $6.41 billion, a price-to-earnings ratio of -14.71 and a beta of 2.86. GRAIL, Inc. has a fifty-two week low of $41.50 and a fifty-two week high of $166.48. The company’s 50-day moving average price is $112.02 and its 200 day moving average price is $78.55.

GRAIL (NASDAQ:GRAL) last issued its earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. The company had revenue of $44.69 million during the quarter, compared to the consensus estimate of $42.39 million. Research analysts anticipate that GRAIL, Inc. will post -10.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on GRAL. Robert W. Baird increased their target price on GRAIL from $96.00 to $118.00 and gave the stock an “outperform” rating in a report on Tuesday, September 22nd. UBS Group upped their price target on GRAIL from $105.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, October 2nd. Morgan Stanley raised their price objective on GRAIL from $60.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Monday, October 12th. Wall Street Zen raised shares of GRAIL from a “sell” rating to a “hold” rating in a report on Sunday, September 13th. Finally, Guggenheim lifted their price objective on shares of GRAIL from $75.00 to $155.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $119.80.

Insider Transactions at GRAIL

In related news, insider Andrew Partridge sold 7,873 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $146.39, for a total transaction of $1,152,528.47. Following the completion of the transaction, the insider owned 155,865 shares in the company, valued at $22,817,077.35. The trade was a 4.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Aaron Freidin sold 23,619 shares of the company’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $146.39, for a total value of $3,457,585.41. Following the transaction, the chief financial officer owned 225,364 shares of the company’s stock, valued at approximately $32,991,035.96. The trade was a 9.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 129,944 shares of company stock worth $14,832,805. 1.83% of the stock is currently owned by company insiders.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.